查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733428

全球再生障碍性贫血市场：市场规模（按类型、应用和地区划分）、未来预测

Global Acquired Aplastic Anemia Market Size By Type (Diagnosis and Treatment), By Application (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

后天性再生障碍性贫血市场规模及预测

预计在预测期内（即 2024 年至 2032 年），获得性再生障碍性贫血市场的收益和市场规模将以显着的复合年增长率呈指数级增长。

后天性再生障碍性贫血市场规模的成长主要归因于血液疾病盛行率的增加、资金筹措、医疗保险覆盖范围以及血液疾病的意识提升计划。全球再生障碍性贫血市场报告对市场进行了全面评估。它对关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球再生障碍性贫血市场

后天性再生障碍性贫血是一种罕见的严重血液疾病，其特征是骨髓无法产生血球。骨髓位于骨骼的中心，看起来像海绵状物质。骨髓负责产生红血球以及其他血液成分。再生障碍性贫血有两种：后天性再生障碍性贫血和遗传性再生障碍性贫血。后天性再生障碍性贫血更为常见，儘管可能是暂时的，但比遗传性再生障碍性贫血更为罕见。

后天性再生障碍性贫血的病因包括杀虫剂、砷和苯等毒素、放射和化疗以及肝炎、EB病毒巨细胞病毒、细小病毒 B19 和 HIV 等感染疾病。以及狼疮和类风湿性关节炎等自体免疫疾病。身体其他部位的癌症可能扩散至骨骼并导致后天性再生障碍性贫血。这种疾病主要影响儿童、青少年和年轻人。此疾病的治疗方法是支持性的，取决于严重程度。

全球再生不良性贫血市场概况

血液疾病盛行率的不断上升预计将推动全球再生障碍性贫血市场的发展。例如，根据美国疾病管制与美国中心的数据，每 5,000 名男性新生儿中就有 1 名患有A型血友病 A，每年约有 400 名婴儿出生时患有A型血友病此外，人们对再生障碍性贫血和血液疾病的认识不断提高可能会推动全球市场的成长。

例如，再生障碍性贫血和骨髓增生异常综合症国际基金会、NORD-国家罕见疾病组织和 CancerIndex 都在致力于提高人们对再生障碍性贫血的认识。 2019 年 2 月，再生障碍性贫血信託基金会春季宣传宣传活动启动。此外，预测期内政府对研发的支持增加、生活方式的改变以及技术的快速发展预计将推动市场成长。

此外，罕见病患疾病率的上升、对更好治疗的需求的增加、对生物技术和製药行业研发的投资的增加以及资金的可用性正在推动市场的成长。然而，治疗成本的上升可能会在预测期内减缓市场成长。治疗费用是影响治疗方法选择的主要因素。在美国，一次骨髓移植的费用超过30万美元。因此，高昂的治疗费用可能会阻碍再生障碍性贫血治疗市场的成长。

目录

第 1 章。全球再生障碍性贫血市场：简介

  • 市场概览
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球再生不良性贫血市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球再生不良性贫血市场（按类型）

  • 概述
  • 诊断
  • 治疗

6. 全球再生不良性贫血市场（依应用）

  • 概述
  • 医院
  • 诊所
  • 其他的

7. 全球再生不良性贫血市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东

第八章全球再生不良性贫血市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Pfizer Inc.
  • Bayer AG
  • Novo Nordisk AS
  • Shire
  • SOBI
  • Octapharma
  • CSL Limited
  • Amgen Inc.
  • GlaxoSmithKline plc.
  • Bluebird bio

第十章 附录

  • 相关分析
简介目录
Product Code: 69301

Acquired Aplastic Anemia Market Size And Forecast

Acquired Aplastic Anemia Market is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecasted period i.e. 2024 to 2032.

The Acquired Aplastic Anemia market size growth is majorly attributed to the increasing prevalence of blood disorders, raising funding, healthcare insurance coverage, and awareness programs for blood disorders. The Global Acquired Aplastic Anemia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Acquired Aplastic Anemia Market Definition

Acquired Aplastic Anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components. Aplastic anemia has two manifestations, i.e. Acquired Aplastic Anemia and inherit aplastic anemia Acquired Aplastic Anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia.

Various causes of Acquired Aplastic Anemia include toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause Acquired Aplastic Anemia. The disease occurs mainly in children, teenagers and young adults. The supportive treatments of this disease are available, which depend on the severity of the condition.

Global Acquired Aplastic Anemia Market Overview

An increase in the prevalence of blood disorders is anticipated to drive the global aplastic anemia market. For instance, according to the Centers for Disease Control and Prevention, in the U.S., haemophilia A affects 1 in 5,000 male newborns and about 400 babies are born with haemophilia A each year; an estimated incidence of hemophilia is 1 per 12,000 annually. In addition, an increase in awareness about aplastic anemia and blood disorders is likely to fuel the growth of the global market.

For instance, The Aplastic Anemia and MDS International Foundation, NORD - National Organization for Rare Disorders, Inc., and CancerIndex, among others, are spreading awareness about aplastic anemia. In February 2019, The Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period.

Moreover, the Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. However, the high cost of the treatment may slow the market growth during the period. The cost of treatment is a major factor influencing the selection of the treatment. The cost of a bone marrow transplant is more than US$ 300,000. Thus, the high cost of the treatment is likely to hamper the growth of the aplastic anemia treatment market.

Global Acquired Aplastic Anemia Market: Segmentation Analysis

The Global Acquired Aplastic Anemia Market is segmented based on Type, Application, and Geography.

Acquired Aplastic Anemia Market, By Type

  • Diagnosis
  • Treatment

Based on Type, the market is bifurcated into Diagnosis and Treatment. The Treatment segment is expected to inflate the market growth.

Acquired Aplastic Anemia Market, By Application

  • Hospitals
  • Clinics
  • Others
  • Acquired Aplastic Anemia Market By Application

Based on Application, the market is bifurcated into Hospitals, Clinics, Other. Hospitals are anticipated to become the fastest-growing market in the forecast duration.

Acquired Aplastic Anemia Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Acquired Aplastic Anemia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominate the global Acquired Aplastic Anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Key Players

The "Global Acquired Aplastic Anemia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc., Bayer AG, Novo Nordisk AS, Shire, SOBI, Octapharma, CSL Limited, Amgen Inc., GlaxoSmithKline plc., and Bluebird bio. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In June 2021, Heartseed and Novo Nordisk will enter into a global collaboration and licensing agreement for stem cell-based heart failure therapy. Except for Japan, Novo Nordisk will have exclusive rights to develop, manufacture, and commercialize HS-001 internationally. Heartseed will retain the exclusive rights to develop HS-001 in Japan, while Novo Nordisk will co-commercialize the product with Heartseed in Japan on a 50/50 profit and cost-sharing basis.
  • The Food and Drug Administration approved Novartis AG's Promacta as a first-line treatment for aplastic anemia in November 2018.
  • Mergers and Acquisitions
  • Amgen announced on April 16, 2021, that it had completed its previously announced tender offer to buy all outstanding shares of common stock of Five Prime Therapeutics, a clinical-stage biotechnology firm focused on immuno-oncology and targeted cancer medicines, for $38.00 per share in cash. After subtracting relevant transaction fees and expenditures, Amgen will pay approximately $1.9 billion in total consideration to complete the tender offer and subsequent merger.
  • Bayer acquires Asklepios BioPharmaceutical (AskBio) in December 2020 and introduces a new cell and gene therapy platform within the Pharmaceuticals Division. Bayer is now one of the industry's leaders in this rapidly expanding field.
  • In November 2020, Novo Nordisk A/S announced the signing of a formal agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery firm with proprietary technologies, such as the Eligen(R) SNAC technology, that enable therapeutic oral formulations.
  • Product Launches and Product Expansions
  • Promacta, the first-line treatment for aplastic anemia, was approved by the Food and Drug Administration (FDA) in November 2018. Novartis AG introduced it. Novartis AG recently gained permission for Revolade, which is used to treat aplastic anemia in adults.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ACQUIRED APLASTIC ANEMIA MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Diagnosis
  • 5.3 Treatment

6 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Other

7 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East

8 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Bayer AG
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Novo Nordisk AS
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Shire
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 SOBI
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Octapharma
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 CSL Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Amgen Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 GlaxoSmithKline plc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Bluebird bio
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research